Orthocell H1 Loss Of A$5.2 Million Tests Bullish Growth Narrative

Simply Wall St.

Yesterday

AdvertisementOrthocell H1 2026 Earnings Snapshot Orthocell (ASX:OCC) has released its H1 2026 results, reporting revenue of A$5.4 million and a basic EPS loss of A$0.021, alongside a net loss of A$5.2...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2614208192"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2614208192\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2614208192?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-02-25 16:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614208192","market":"us","top_or_hot":-1,"title":"Orthocell H1 Loss Of A$5.2 Million Tests Bullish Growth Narrative","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementOrthocell H1 2026 Earnings Snapshot Orthocell (ASX:OCC) has released its H1 2026 results, reporting revenue of A$5.4 million and a basic EPS loss of A$0.021, alongside a net loss of A$5.2...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-occ/orthocell-shares/news/orthocell-h1-loss-of-a52-million-tests-bullish-growth-narrat\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orthocell H1 Loss Of A$5.2 Million Tests Bullish Growth Narrative</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrthocell H1 Loss Of A$5.2 Million Tests Bullish Growth Narrative\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-25 16:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-occ/orthocell-shares/news/orthocell-h1-loss-of-a52-million-tests-bullish-growth-narrat><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementOrthocell H1 2026 Earnings Snapshot Orthocell (ASX:OCC) has released its H1 2026 results, reporting revenue of A$5.4 million and a basic EPS loss of A$0.021, alongside a net loss of A$5.2...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-occ/orthocell-shares/news/orthocell-h1-loss-of-a52-million-tests-bullish-growth-narrat\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7508","symbol_name":"医药生物股","start_time":0,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-occ/orthocell-shares/news/orthocell-h1-loss-of-a52-million-tests-bullish-growth-narrat","article_id":"2614208192","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-occ/orthocell-shares/news/orthocell-h1-loss-of-a52-million-tests-bullish-growth-narrat","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2614208192","pubTimestamp":1772007687,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Orthocell H1 2026 Earnings Snapshot\nOrthocell (ASX:OCC) has released its H1 2026 results, reporting revenue of A$5.4 million and a basic EPS loss of A$0.021, alongside a net loss of A$5.2 million. The company’s revenue moved from A$3.6 million in H1 2025 to A$5.1 million in H2 2025 and A$5.4 million in H1 2026. Over the same periods, basic EPS shifted from a loss of A$0.006 in H1 2025 to A$0.031541 in H2 2025 and A$0.021 in H1 2026. For investors, the latest results keep the focus on how...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7508":"医药生物股","OCC.AU":"ORTHOCELL LTD","BLSX":"Tradr 2X Long BLSH Daily ETF","BLSG":"2倍做多BLSH ETF-Leverage Shares","BK4112":"金融交易所和数据","BK7067":"生物科技"},"translate_title":"Orthocell上半年亏损520万澳元考验看涨增长叙事","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OCC.AU":1.98,"BLSG":0.6,"BLSX":0.6},"content_text":"AdvertisementOrthocell H1 2026 Earnings Snapshot Orthocell (ASX:OCC) has released its H1 2026 results, reporting revenue of A$5.4 million and a basic EPS loss of A$0.021, alongside a net loss of A$5.2 million. The company’s revenue moved from A$3.6 million in H1 2025 to A$5.1 million in H2 2025 and A$5.4 million in H1 2026. Over the same periods, basic EPS shifted from a loss of A$0.006 in H1 2025 to A$0.031541 in H2 2025 and A$0.021 in H1 2026. For investors, the latest results keep the focus on how quickly revenue can scale relative to ongoing losses and what that may imply for margins over time. See our full analysis for Orthocell. With the headline numbers now available, the next step is to see how this earnings profile aligns with the broader narratives investors have about Orthocell, and where those narratives might warrant a reassessment. Curious how numbers become stories that shape markets? Explore Community Narratives ASX:OCC Revenue & Expenses Breakdown as at Feb 2026 Losses widen to A$5.2 million on higher H1 spend  H1 2026 net loss was A$5.2 million on A$5.4 million of revenue, compared with a A$1.3 million loss on A$3.6 million of revenue in H1 2025 and a A$7.3 million loss on A$5.1 million of revenue in H2 2025, so the company is still spending more than it brings in over each half year. Bears focus on this unprofitable profile and the trailing 12 month net loss of A$12.5 million, and that view is reflected in concerns about ongoing negative earnings and the need to justify current spending levels against the revenue base.\n     They point to basic EPS over the last three halves, which has stayed in loss territory between A$0.006 and A$0.031541 per share, as evidence that recent revenue shifts have not yet translated into positive earnings. The trailing 12 month basic EPS of A$0.052151 loss underscores that, over a full year window, losses are still meaningful even as management has reduced losses over five years at an average rate of 2.7% a year.    Over the last few halves, some investors have argued that Orthocell is still a long way from turning its revenue into sustainable profits, so it can be helpful to see a structured bear case before you decide how you feel about the current spending and loss levels. 🐻 Orthocell Bear Case Revenue growth forecasts versus current A$9.3 million base  The trailing 12 month revenue sits at A$9.3 million, compared with half year revenues of A$3.6 million in H1 2025, A$5.1 million in H2 2025, and A$5.4 million in H1 2026, and the provided data cites a forecast revenue growth rate of about 45.8% a year against an Australian market forecast of 6% a year. Bullish investors lean on that 45.8% forecast growth rate, arguing that a relatively small revenue base and multiple product lines can support faster top line expansion than the broader market, but the current loss of A$12.5 million over the trailing 12 months keeps the focus on how much extra revenue is needed for earnings to catch up.\n     Supporters highlight that revenue in the last three halves has been above A$3.6 million in each period and above A$5 million in the last two, seeing this as a platform to apply the forecast growth rate. At the same time, the A$12.5 million trailing 12 month loss means any bullish growth story has to account for ongoing spending that is still larger than the current revenue base by several million dollars a year.    High 27.8x P/S and DCF fair value gap  The shares trade at A$0.96 with a P/S of 27.8x, compared with a peer average of 10.4x and an Australian biotech industry average of 16.7x, while the provided DCF fair value of A$2.88 flags a gap between the current share price and that valuation model. What stands out for investors is the tension between critics who point to the premium 27.8x P/S multiple on a A$9.3 million trailing 12 month revenue base, and those who highlight the DCF fair value being about three times the current share price, and both sides are using the same set of numbers to make very different points about valuation and growth expectations.\n     Skeptics emphasise that paying well above the 10.4x peer and 16.7x industry P/S averages leaves less room for error if revenue or earnings do not track the 45.8% forecast growth rate. Supporters counter that a DCF fair value of A$2.88 versus a A$0.96 share price, along with a multi year trend of losses narrowing at about 2.7% a year, suggests the current market price does not fully reflect the growth assumptions baked into that model.    If you want to see how other investors square that rich P\nNext Steps Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Orthocell's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move. After all this, do you feel the market is too cautious or too optimistic here, and are you ready to make up your own mind quickly based on the numbers and context in front of you? To see what the positive angles look like in detail, take a moment to review 2 key rewards. See What Else Is Out There Orthocell is still posting meaningful losses against a small A$9.3 million revenue base while trading on a premium 27.8x P/S multiple. If those ongoing losses and the rich revenue multiple make you cautious, take a closer look at our 6 resilient stocks with low risk scores to quickly narrow in on companies with steadier profiles.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}